文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

作者信息

Pietersz G A, Li W, Osinski C, Apostolopoulos V, McKenzie I F

机构信息

The Austin Research Institute, Studley Rd, Heidelberg, Australia.

出版信息

Vaccine. 2000 Apr 3;18(19):2059-71. doi: 10.1016/s0264-410x(99)00515-0.


DOI:10.1016/s0264-410x(99)00515-0
PMID:10706970
Abstract

Mucin1 (MUC1) is expressed ubiquitously on breast cancer cells and is a potential target for the generation of cytotoxic T cells for vaccination against breast cancer. Thus far studies of the immunogenicity of MUC1 have used peptides from the variable number of tandem repeat (VNTR); mice so immunised can generate strong cellular and antibody responses to the VNTR of human MUC1. We now demonstrate that significant CTL and CTLp can be induced to other regions of MUC1. Using the whole native MUC1 molecule, the human milk fat globule membrane antigen (HMFG) linked to mannan, cytotoxic T cell precursors (CTLp) can be generated in BALB/c, C57BL/6, transgenic HLA-A0201/K(b) and double transgenic HLA-A0201/K(b)xhuman MUC1 (A2 K(b)MUC1) mice. By immunising with HMFG and testing selectively on (a) extracellular (non-VNTR); (b) VNTR and (c) intracellular peptides, it was shown that all three regions generated effective CTL. Further, the CTL responses to non-VNTR peptides were as strong as those generated to the VNTR. Epitope prediction algorithms were not particularly helpful to describe CTL epitopes: overlapping peptides had to be synthesised and tested to find the epitopes. Thus, for CTL generation, the whole HMFG molecule is a powerful immunogen when linked to mannan, especially as multiple peptide epitopes for presentation by many Class I molecules are contained within the one molecule. Furthermore, Class I restricted MUC1 CTL were generated in double transgenic A2 K(b)MUC1 mice by immunising with mannan-native mucin (HMFG), suggesting that tolerance to MUC1 can be overcome with mannan-HMFG.

摘要

相似文献

[1]
Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

Vaccine. 2000-4-3

[2]
T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.

Int Immunopharmacol. 2005-2

[3]
Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.

Int J Cancer. 2000-2-1

[4]
Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.

Int J Cancer. 2001-2-1

[5]
MHC-restricted presentation of a single repeat of MUC1 mucin.

Immunol Invest. 2007

[6]
Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.

J Immunol. 1997-12-1

[7]
The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

Vaccine. 2000-8-1

[8]
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

Blood. 1999-6-15

[9]
Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope.

Molecules. 2018-9-2

[10]
The immunogenicity of MUC1 peptides and fusion protein.

Cancer Lett. 1995-3-23

引用本文的文献

[1]
Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.

Iran J Basic Med Sci. 2018-1

[2]
Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides.

Molecules. 2015-8-3

[3]
Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.

BMC Infect Dis. 2015-2-26

[4]
Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.

PLoS One. 2012-11-26

[5]
The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.

Clin Exp Immunol. 2009-11

[6]
Mucin immunohistochemistry in the diagnosis and mapping of extramammary Paget's disease.

J Cell Mol Med. 2008

[7]
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Breast Cancer Res. 2006

[8]
An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.

Br J Cancer. 2003-9-15

[9]
MUC1, the renaissance molecule.

J Mammary Gland Biol Neoplasia. 2001-7

[10]
MUC1 in carcinoma-host interactions.

Glycoconj J. 2000

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索